Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 17, 2005, Pages 3912-3916

  Blizzard, Timothy A ^a   DiNinno, Frank ^a   Chen, Helen Y ^a   Kim, Seongkon ^a   Wu, Jane Y ^a   Chan, Wanda ^a   Birzin, Elizabeth T ^a   Yang, Yi Tien ^a   Pai, Lee Yuh ^a   Hayes, Edward C ^a   DaSilva, Carolyn A ^a   Rohrer, Susan P ^a   Schaeffer, James M ^a   Hammond, Milton L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Estrogen; SERAMs; SERMs

Indexed keywords

ANTIESTROGEN; DIHYDROBENZOXATHIIN; ESTROGEN RECEPTOR ALPHA; LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; RAT; UTERUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; OXATHIINS; RATS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; UTERUS;

MINK CELL FOCUS-FORMING VIRUS;

EID: 23244443558     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.05.089     Document Type: Article

References (36)

1. V.C. Jordan J. Med. Chem. 46 2003 883
2. V.C. Jordan J. Med. Chem. 46 2003 1081
3. S. Mosselman, J. Polman, and R. Dijkema FEBS Lett. 392 1996 49
4. G.G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.A. Gustafsson Proc. Natl. Acad. Sci. U.S.A. 93 1996 5925
5. M.S. Malamas, E.S. Manas, R.E. McDevitt, I. Gunawan, Z. Xu, M.D. Collini, C.P. Miller, T. Dinh, R.A. Henderson, J.C. Keith, and H.A. Harris J. Med. Chem. 47 2004 5021
6. M.D. Collini, D.H. Kaufman, E.S. Manas, H.A. Harris, R.A. Henderson, Z.B. Xu, R.J. Unwalla, and C.P. Miller Bioorg. Med. Chem. Lett. 14 2004 4925
7. W. Yang, Y. Wang, Z. Ma, R. Golla, T. Stouch, R. Seethala, S. Johnson, R. Zhou, T. Gungor, J.H.M. Feyen, and J.K. Dickson Bioorg. Med. Chem. Lett. 14 2004 2327
8. C. Yang, R.J. Edsall, H.A. Harris, X. Zhang, E.S. Manas, and R.E. Mewshaw Bioorg. Med. Chem. 12 2004 2553
9. R. Chesworth, M.P. Zawistoski, B.A. Lefker, K.O. Cameron, R.F. Day, F.M. Mangano, R.L. Rosati, S. Colella, D.N. Petersen, A. Brault, B. Lu, L.C. Pan, P. Perry, O. Ng, T.A. Castleberry, T.A. Owen, T.A. Brown, D.D. Thompson, and P. DaSilva-Jardine Bioorg. Med. Chem. Lett. 14 2004 2729
10. M.J. Meyers, J. Sun, K.E. Carlson, G.A. Marriner, B.S. Katzenellenbogen, and J.A. Katzenellenbogen J. Med. Chem. 44 2001 4230
11. D.S. Mortensen, A.L. Rodriguez, K.E. Carlson, J. Sun, B.S. Katzenellenbogen, and J.A. Katzenellenbogen J. Med. Chem. 44 2001 3838
12. R.S. Muthyala, K.E. Carlson, and J.A. Katzenellenbogen Bioorg. Med. Chem. Lett. 13 2003 4485
13. B.R. Henke, T.G. Consler, N. Go, R.L. Hale, D.R. Hohman, S.A. Jones, A.T. Lu, L.B. Moore, J.T. Moore, L.A. Orband-Miller, R.G. Robinett, J. Shearin, P.K. Spearing, E.L. Stewart, P.S. Turnbull, S.L. Weaver, S.P. Williams, G.B. Wisely, and M.H. Lambert J. Med. Chem. 45 2002 5492
14. U. Schopfer, P. Schoefter, S.F. Bischoff, J. Nozulak, D. Feuerbach, and P. Floersheim J. Med. Chem. 45 2002 1399
15. E.S. Manas, R.J. Unwalla, Z.B. Xu, M.S. Malamas, C.P. Miller, H.A. Harris, C. Hsiao, T. Akopian, W.T. Hum, K. Malakian, S. Wolfrom, A. Bapat, R.A. Bhat, M.L. Stahl, W.S. Somers, and J.C. Alvarez J. Am. Chem. Soc. 126 2004 15106
16. S. Kim, J.Y. Wu, E.T. Birzin, K. Frisch, W. Chan, L. Pai, Y.T. Yang, R.T. Mosley, P.M.D. Fitzgerald, N. Sharma, F. DiNinno, S. Rohrer, J.M. Schaeffer, and M.L. Hammond J. Med. Chem. 47 2004 2171
17. H.Y. Chen, S. Kim, J.Y. Wu, E.T. Birzin, W. Chan, Y.T. Yang, F. DiNinno, S. Rohrer, J.M. Schaeffer, and M.L. Hammond Bioorg. Med. Chem. Lett. 14 2004 2551
18. S. Kim, J. Wu, H.Y. Chen, E.T. Birzin, W. Chan, Y.T. Yang, L. Colwell, S. Li, F. DiNinno, S. Rohrer, J.M. Schaeffer, and M.L. Hammond Bioorg. Med. Chem. Lett. 14 2004 2741
19. T.A. Blizzard, F. DiNinno, J.D. Morgan II, H.Y. Chen, J.Y. Wu, C. Gude, S. Kim, W. Chan, E.T. Birzin, Y. Yang, L. Pai, Z. Zhang, E.C. Hayes, C.A. DaSilva, W. Tang, S.P. Rohrer, J.M. Schaeffer, and M.L. Hammond Bioorg. Med. Chem. Lett. 14 2004 3861
20. T.A. Blizzard, F. DiNinno, J.D. Morgan II, J.Y. Wu, H.Y. Chen, S. Kim, W. Chan, E.T. Birzin, Y. Yang, L. Pai, Z. Zhang, E.C. Hayes, C.A. DaSilva, W. Tang, S.P. Rohrer, J.M. Schaeffer, and M.L. Hammond Bioorg. Med. Chem. Lett. 14 2004 3865
21. T.A. Blizzard, F. DiNinno, J.D. Morgan II, H.Y. Chen, J.Y. Wu, S. Kim, W. Chan, E.T. Birzin, Y. Yang, L. Pai, Y. Li, Z. Zhang, E.C. Hayes, C.A. DaSilva, P.M.D. Fitzgerald, N. Sharma, W. Tang, S.P. Rohrer, J.M. Schaeffer, and M.L. Hammond Bioorg. Med. Chem. Lett. 15 2005 107
22. Aldrich Chemical Company.
23. 1H NMR. Selected compounds were characterized further by elemental analysis.
24. Analytical chiral HPLC analysis was performed on a Chiralpak AD 4.6 × 250 mm 10 μm column eluted with 3:1 heptane/isopropanol at 0.4 mL/min. Under these conditions, the major (R,S)-diastereomer of 19 has a retention time of 23.7 min, while the minor (S,S)-diastereomer elutes at 15.1 min.
25. 1H NMR of the Mosher ester clearly showed the presence of only one diastereomer. By contrast, the corresponding NMR spectrum of the Mosher ester of the 1:1 diastereomeric mixture generated using racemic acid as the starting material clearly showed both diastereomers. Similarly, when the reaction sequence was run with racemic acid and racemic amine as starting materials, the NMR spectrum of the Mosher ester of the product showed ≥3 diastereomers.
26. 50 values that are reproducible to within a factor of 2-3. Dihydrobenzoxathiin 1 (n = 36) and estradiol (n > 100) were tested in multiple assays; data reported in Table 1 are an average of all determinations.
27. Data for 7 and 8 reflect a 20 h incubation prior to radioactive quantification; all other data obtained with 3 h incubation.
28. 9c that measures estrogen agonism and antagonism in rat uterine tissue. Compounds are dosed orally at the indicated doses, except for fulvestrant, which was dosed subcutaneously. Agonism is reported as percentage of estradiol control; antagonism reported as percentage antagonism of estradiol.
29. Estradiol exhibited 100% agonism at 4 μg/kg.
30. A.E. Wakeling, B. Valcaccia, E. Newboult, and L.R. Green J. Steroid Biochem. 20 1984 111
31. 50 for the test compound is determined.
32. M. Levin, N. D'Souza, and J. Castaner Drugs Future 26 2001 841
33. Q. Tan, T.A. Blizzard, J.D. Morgan II, E.T. Birzin, W. Chan, Y. Yang, L. Pai, E.C. Hayes, C.A. DaSilva, S.W. Mitra, J. Yudkovitz, H.A. Wilkinson, N. Sharma, P.M.D. Fitzgerald, S. Li, L. Colwell, J.E. Fisher, S. Adamski, A.A. Reszka, D. Kimmel, F. DiNinno, S.P. Rohrer, L.P. Freedman, J.M. Schaeffer, and M.L. Hammond Bioorg. Med. Chem. Lett. 15 2005 1675
34. Hayes, E. C. et al., manuscript in preparation.
35. C.K. Osborne, A. Wakeling, and R.I. Nicholson Br. J. Cancer 90 2004 S2
36. Warrier, S. et al., manuscript in preparation.